These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 25119042)

  • 21. Polycomb Repressor Complex 2 in Genomic Instability and Cancer.
    Veneti Z; Gkouskou KK; Eliopoulos AG
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
    Puda A; Milosevic JD; Berg T; Klampfl T; Harutyunyan AS; Gisslinger B; Rumi E; Pietra D; Malcovati L; Elena C; Doubek M; Steurer M; Tosic N; Pavlovic S; Guglielmelli P; Pieri L; Vannucchi AM; Gisslinger H; Cazzola M; Kralovics R
    Am J Hematol; 2012 Mar; 87(3):245-50. PubMed ID: 22190018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.
    Ntziachristos P; Tsirigos A; Van Vlierberghe P; Nedjic J; Trimarchi T; Flaherty MS; Ferres-Marco D; da Ros V; Tang Z; Siegle J; Asp P; Hadler M; Rigo I; De Keersmaecker K; Patel J; Huynh T; Utro F; Poglio S; Samon JB; Paietta E; Racevskis J; Rowe JM; Rabadan R; Levine RL; Brown S; Pflumio F; Dominguez M; Ferrando A; Aifantis I
    Nat Med; 2012 Feb; 18(2):298-301. PubMed ID: 22237151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
    Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis.
    Ma X; Wang J; Wang J; Ma CX; Gao X; Patriub V; Sklar JL
    Oncotarget; 2017 Jan; 8(3):4062-4078. PubMed ID: 27845897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
    Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
    Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The polycomb repressive complex 2 is a potential target of SUMO modifications.
    Riising EM; Boggio R; Chiocca S; Helin K; Pasini D
    PLoS One; 2008 Jul; 3(7):e2704. PubMed ID: 18628979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.
    Reuss DE; Mucha J; Hagenlocher C; Ehemann V; Kluwe L; Mautner V; von Deimling A
    PLoS One; 2013; 8(2):e57152. PubMed ID: 23437333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Competition between PRC2.1 and 2.2 subcomplexes regulates PRC2 chromatin occupancy in human stem cells.
    Youmans DT; Gooding AR; Dowell RD; Cech TR
    Mol Cell; 2021 Feb; 81(3):488-501.e9. PubMed ID: 33338397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
    Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
    Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
    Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective inhibition of tumor oncogenes by disruption of super-enhancers.
    Lovén J; Hoke HA; Lin CY; Lau A; Orlando DA; Vakoc CR; Bradner JE; Lee TI; Young RA
    Cell; 2013 Apr; 153(2):320-34. PubMed ID: 23582323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.
    Korfhage J; Lombard DB
    Mol Cancer Res; 2019 Jul; 17(7):1417-1428. PubMed ID: 31023785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis.
    Dai C; Santagata S; Tang Z; Shi J; Cao J; Kwon H; Bronson RT; Whitesell L; Lindquist S
    J Clin Invest; 2012 Oct; 122(10):3742-54. PubMed ID: 22945628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL.
    Andrieu GP; Kohn M; Simonin M; Smith CL; Cieslak A; Dourthe MÉ; Charbonnier G; Graux C; Huguet F; Lhéritier V; Dombret H; Spicuglia S; Rousselot P; Boissel N; Asnafi V
    Blood; 2021 Nov; 138(19):1855-1869. PubMed ID: 34125178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
    García-Carpizo V; Sarmentero J; Han B; Graña O; Ruiz-Llorente S; Pisano DG; Serrano M; Brooks HB; Campbell RM; Barrero MJ
    Sci Rep; 2016 Sep; 6():32952. PubMed ID: 27604143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
    Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.